Hvivo on track for Growth Targets with Record Year in 2023

Hvivo, a pharmaceutical services company formerly known as Open Orphan, said it remained on track to hit its future growth targets after another record year in 2023.

The company is set to begin paying annual dividends, subject to approval at the upcoming annual general meeting, with around £1.4 million (€1.63m) shared out among shareholders at 0.20p per ordinary share. The company paid a one-off special dividend of £3.1 million in 2023.

Revenue at the company, which specialises in testing infectious and respiratory disease products, rose 16 per cent to £56 million, and expects to hit £64 million this year, it said, as its human challenge trials business showed organic growth. 

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    hVIVO plc

    More articles like this

    hVIVO plc

    Accelerating vaccine development to combat the tripledemic

    The recent rise of the “tripledemic” – the simultaneous spread of the influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) – is posing significant risks, especially to older adults and those with chronic conditions or compromised

    hVIVO plc

    hVIVO plc announce Phase 2b Influenza Field Study Contract

    Highlights ·    hVIVO to enrol up to 1,000 healthy volunteers as part of a multicenter field study testing an influenza drug candidate, with hVIVO selected as the sole UK clinical site ·    Largest field study contract supporting a new income

    hVIVO plc

    The last smallpox outbreak and the future of vaccination

    Fifty years ago this month, India experienced its final seasonal smallpox epidemic. Nearly 200,000 infections were recorded, resulting in over 30,000 deaths. By May 1975, the last case of smallpox in India was diagnosed, and in

    hVIVO plc

    Travellers vaccines and the role of Human Challenge Trials

    A travellers’ vaccine is administered to individuals from non-endemic regions before they travel to areas where certain diseases are prevalent. These vaccines are crucial for travel medicine, protecting travellers and preventing the importation of vaccine-preventable diseases

    hVIVO plc

    hVIVO secures contract for Omicron characterisation study

    In June 2024, hVIVO announced a £2.5 million contract with a mid-sized pharmaceutical company to launch an Omicron characterisation study. This study aims to determine a dose of hVIVO’s Omicron BA.5 challenge agent that establishes a

    hVIVO plc

    hVIVO signs £2.5m contract for Omicron characterisation study

    hVIVO plc (LON:HVO), a fast growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it has signed a £2.5m contract with a mid-sized pharmaceutical company

    hVIVO plc

    Clinical Trial participation and eligibility requirements

    People who haven’t had the opportunity to participate in a clinical trial often wonder about eligibility criteria. Each trial has its own goals and purposes, so the inclusion criteria vary. Many trials require participants with specific

    hVIVO plc

    A complete guide to Clinical Trials

    Clinical trials play a vital role in the discovery, testing, and eventual marketing of new drugs. Over a million individuals participated in clinical trials during 2022/23, involving more than 6,000 studies. Understanding eligibility criteria for clinical

    hVIVO plc

    Importance of Clinical Trials in the medical industry

    Clinical trials play an important role in helping to ensure new drugs can be discovered, tested for safety and efficacy, and ultimately make their way onto the market. Over a million people took part in clinical trials during

    hVIVO plc

    European Mediscience Awards 2024 shortlist announced

    The European Mediscience Awards is now in its 22nd year, having been held every year since inception in 2002*. The event is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe.